BCL2 and breast carcinoma: It has recently been reported that BKM120 in combination with trastuzumab is beneficial in trastuzumab-resistant breast cancer.62 Other PI3K inhibitors, including LY294002 and buparlisib, have also been proven to have greater clinical efficacy combined with endocrine therapy.63, 64 In some other solid tumors, BKM120 has been reported to synergistically work with an mTOR inhibitor RAD001 and a Bcl-2 inhibitor ABT-737 in suppression of lung cancer18 and glioblastoma cell growth,19 respectively.